Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that 
Disaster or digital spectacle? The dangers of using floods to create social media content 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Gold and Asian Stocks Rebound as Market Volatility Eases and Global Sentiment Improves 
Dollar Holds Firm as Strong U.S. Data, Fed Expectations and Global Central Bank Moves Shape Markets 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Why financial hardship is more likely if you’re disabled or sick 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
RBA Raises Interest Rates by 25 Basis Points as Inflation Pressures Persist 
Stuck in a creativity slump at work? Here are some surprising ways to get your spark back 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
